These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38274979)

  • 1. Human leukocyte antigen alloimmunization prevention mechanisms in blood transfusion.
    Adane T; Enawgaw B
    Asian J Transfus Sci; 2023; 17(2):264-272. PubMed ID: 38274979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
    Saris A; Pavenski K
    Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Storage-Induced Platelet Apoptosis Is a Potential Risk Factor for Alloimmunization Upon Platelet Transfusion.
    Saris A; Peyron I; van der Meer PF; Stuge TB; Zwaginga JJ; van Ham SM; Ten Brinke A
    Front Immunol; 2018; 9():1251. PubMed ID: 29951051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management.
    Panch SR; Guo L; Vassallo R
    Blood Rev; 2023 Nov; 62():101135. PubMed ID: 37805287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced alloimmunization in mice following repeated transfusion with pathogen-reduced platelets.
    Muench MO; Heitman JW; Inglis H; Fomin ME; Marschner S; Goodrich RP; Norris PJ; Jackman RP
    Transfusion; 2016 Jun; 56(6):1419-29. PubMed ID: 27028210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management.
    Pavenski K; Freedman J; Semple JW
    Tissue Antigens; 2012 Apr; 79(4):237-45. PubMed ID: 22385314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial.
    van Marwijk Kooy M; van Prooijen HC; Moes M; Bosma-Stants I; Akkerman JW
    Blood; 1991 Jan; 77(1):201-5. PubMed ID: 1984797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components--a randomized trial.
    Oksanen K; Kekomäki R; Ruutu T; Koskimies S; Myllylä G
    Transfusion; 1991 Sep; 31(7):588-94. PubMed ID: 1891788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. White blood cell inactivation after treatment with riboflavin and ultraviolet light.
    Marschner S; Fast LD; Baldwin WM; Slichter SJ; Goodrich RP
    Transfusion; 2010 Nov; 50(11):2489-98. PubMed ID: 20529002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current trends in platelet transfusions practice: The role of ABO-RhD and human leukocyte antigen incompatibility.
    Valsami S; Dimitroulis D; Gialeraki A; Chimonidou M; Politou M
    Asian J Transfus Sci; 2015; 9(2):117-23. PubMed ID: 26420927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of patients refractory to platelet transfusion.
    Chockalingam P; Sacher RA
    J Infus Nurs; 2007; 30(4):220-5. PubMed ID: 17667077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
    Amemiya Y
    Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Leukocyte depletion of blood products and anti-HLA immunization].
    Valla A
    Rev Fr Transfus Hemobiol; 1993 Jun; 36(3):281-91. PubMed ID: 8347251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevention of platelet transfusion refractoriness and HLA alloimmunization by leukocyte filtered platelet transfusion: a meta analysis].
    Yuan Q; Chen X; Cheng L; Zhou CH; Fu XM; Li YP; Wang NH; Wang L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Aug; 33(4):412-20. PubMed ID: 21906451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study.
    Sintnicolaas K; van Marwijk Kooij M; van Prooijen HC; van Dijk BA; van Putten WL; Claas FH; Novotny VM; Brand A
    Blood; 1995 Feb; 85(3):824-8. PubMed ID: 7833483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Red blood cell alloantibodies are associated with increased alloimmunization against human leukocyte antigens.
    Belizaire R; Mack J; Kadauke S; Kim Y; Saidman S; Makar RS
    Transfusion; 2019 Jul; 59(7):2256-2263. PubMed ID: 30980544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of refractoriness and HLA-alloimmunization using filtered blood products.
    Sniecinski I; O'Donnell MR; Nowicki B; Hill LR
    Blood; 1988 May; 71(5):1402-7. PubMed ID: 3282572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Refractory effect and alloimmunization after transfusion of thrombocytes].
    Volkova RI; Agranenko VA
    Gematol Transfuziol; 1992 Feb; 37(2):16-21. PubMed ID: 1426903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
    Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
    Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation.
    Wong M; Narra R; Selim M; Zimmerman MA; Kim J; Padmanabhan A; Hong JC
    J Surg Res; 2020 Nov; 255():99-105. PubMed ID: 32543385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.